A randomized multicenter, double-blind, placebo-controlled comparison of chemotherapy plus trastuzumab plus placebo versus chemotherapy plus trastuzumab plus pertuzumab as adjuvant therapy in patients with operable HRE2-positive primary breast cancer
- Harris, Marion (Primary Chief Investigator (PCI))
Project: Research